Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.

Cancer medicine - 1 Aug 2023

Hao Yue, Xu Manyi, Jin Jianan, Si Jinfei, Xu Chunwei, Song Zhengbo

Abstract excerpt

BACKGROUND: The efficacy of definite for non-small-cell lung cancer (NSCLC) with uncommon epidermal growth factor receptor (EGFR) mutations has been preliminarily demonstrated. However, there is a paucity of data with which to compare the efficacy and safety of second- and third-generation TKIs in patients with NSCLC carrying uncommon EGFR mutations. METHODS: We compared the efficacy and safety of second- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 37306192
DOI: 10.1002/cam4.6229
PMCID: PMC10469645

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Comparison of efficacy and safety of second- and third-generation TKIs for non-small-cell lung cancer with uncommon EGFR mutations.PMID 37306192Read ↗

Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.Semantic proximity Read ↗

Chemotherapy outcomes in EGFR-TKI resistant patients with common and uncommon EGFR mutation: An exploratory retrospective cohort study.Semantic proximity Read ↗

Effectiveness of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer patients with uncommon EGFR mutations: A multicenter observational study.Semantic proximity Read ↗

The advance of the third‑generation EGFR‑TKI in the treatment of non‑small cell lung cancer (Review).Semantic proximity Read ↗

Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs).Semantic proximity Read ↗

Second-line therapy with first- or second-generation tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer patients with T790M-negative or unidentified mutation.Semantic proximity Read ↗

Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review.Semantic proximity Read ↗

Hitting the Right Spot: Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.Semantic proximity Read ↗

Befotertinib in first-line treatment for Chinese non-small cell lung cancer patients harboring common EGFR-mutations reveals similar efficacy to other third-generation EGFR-TKIs but somewhat different safety profileSemantic proximity Read ↗

Comparative efficacy and safety of first, second, and third-generation EGFR tyrosine kinase inhibitors in treatment-naïve EGFR-mutant advanced non-small cell lung cancer: a systematic review and network meta-analysis of randomized controlled trials.Semantic proximity Read ↗

A systematic review and meta-analysis on effectiveness and safety of traditional Chinese medicine combined with EGFR-TKIs in treating advanced non-small cell lung cancerSemantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data from Taiwan.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.